NR 546 Final Exam V2 | NR 546 Advanced
Psychopharmacology | Chamberlain | Q&A
with Rationale (Chamberlain NR546 Final
Exam)
1. A patient diagnosed with schizophrenia presents with significant positive symptoms
including hallucinations and delusions. Which dopaminergic pathway is primarily implicated
in the manifestation of these symptoms?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
Answer: C
Rationale: The mesolimbic pathway is associated with the positive symptoms of
schizophrenia due to an overabundance of dopamine. Excessive dopaminergic activity in
this area leads to hallucinations, delusions, and thought disorders. Most antipsychotic
medications aim to block D2 receptors in this pathway to alleviate these symptoms.
2. Which antipsychotic medication requires the provider to monitor the patient’s Absolute
Neutrophil Count (ANC) via the REMS program?
A. Quetiapine
,B. Clozapine
C. Risperidone
D. Olanzapine
Answer: B
Rationale: Clozapine carries a black box warning for agranulocytosis, which is a severe and
potentially fatal decrease in white blood cell counts. The Risk Evaluation and Mitigation
Strategy (REMS) program mandates regular blood monitoring to ensure patient safety. If
the ANC falls below a specific threshold, the medication must be discontinued immediately
to prevent life-threatening infections.
3. A patient taking Lithium for Bipolar I Disorder complains of tremors and confusion. The
serum lithium level is found to be 1.8 mEq/L. How should the provider interpret this finding?
A. The level is toxic and requires immediate intervention.
B. The level indicates sub-therapeutic dosing.
C. The level is within the therapeutic range.
D. The level is normal for an acute manic episode.
Answer: A
Rationale: The standard therapeutic range for lithium is generally between 0.6 and 1.2
mEq/L. Levels above 1.5 mEq/L are considered toxic and can lead to severe neurological
,and renal complications. Manifestations such as ataxia, coarse tremors, and confusion are
clinical indicators that the dosage needs to be reduced or stopped.
4. Which antidepressant is contraindicated in patients with a history of seizure disorders or
eating disorders?
A. Sertraline
B. Escitalopram
C. Fluoxetine
D. Bupropion
Answer: D
Rationale: Bupropion is known to lower the seizure threshold, making it dangerous for
individuals with pre-existing seizure conditions. Furthermore, it is contraindicated in
patients with anorexia or bulimia due to an increased risk of seizures in those with
electrolyte imbalances. Providers must screen for these conditions before initiating
treatment with this norepinephrine-dopamine reuptake inhibitor.
5. A patient is started on Lamotrigine for mood stabilization. What is the most critical
education the provider must provide regarding adverse effects?
A. The risk of significant weight gain
B. The requirement for weekly blood draws
C. The possibility of developing a life-threatening rash
, D. The high risk of developing diabetes
Answer: C
Rationale: Lamotrigine is associated with Stevens-Johnson Syndrome (SJS), a rare but
potentially fatal dermatological reaction. Patients must be instructed to stop the
medication and seek emergency care at the first sign of a skin rash or mucosal lesion. Slow
titration of the dosage is required to minimize the risk of this severe hypersensitivity
reaction.
6. In the treatment of Alzheimer’s disease, what is the primary mechanism of action of
Donepezil?
A. NMDA receptor antagonism
B. Dopamine reuptake inhibition
C. Serotonin receptor agonism
D. Acetylcholinesterase inhibition
Answer: D
Rationale: Donepezil works by inhibiting the enzyme acetylcholinesterase, which is
responsible for breaking down acetylcholine in the synaptic cleft. By increasing the
availability of acetylcholine, the medication helps to improve cognitive function and
memory in patients with dementia. This pharmacological approach focuses on
compensating for the cholinergic deficit observed in Alzheimer’s pathology.
Psychopharmacology | Chamberlain | Q&A
with Rationale (Chamberlain NR546 Final
Exam)
1. A patient diagnosed with schizophrenia presents with significant positive symptoms
including hallucinations and delusions. Which dopaminergic pathway is primarily implicated
in the manifestation of these symptoms?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
Answer: C
Rationale: The mesolimbic pathway is associated with the positive symptoms of
schizophrenia due to an overabundance of dopamine. Excessive dopaminergic activity in
this area leads to hallucinations, delusions, and thought disorders. Most antipsychotic
medications aim to block D2 receptors in this pathway to alleviate these symptoms.
2. Which antipsychotic medication requires the provider to monitor the patient’s Absolute
Neutrophil Count (ANC) via the REMS program?
A. Quetiapine
,B. Clozapine
C. Risperidone
D. Olanzapine
Answer: B
Rationale: Clozapine carries a black box warning for agranulocytosis, which is a severe and
potentially fatal decrease in white blood cell counts. The Risk Evaluation and Mitigation
Strategy (REMS) program mandates regular blood monitoring to ensure patient safety. If
the ANC falls below a specific threshold, the medication must be discontinued immediately
to prevent life-threatening infections.
3. A patient taking Lithium for Bipolar I Disorder complains of tremors and confusion. The
serum lithium level is found to be 1.8 mEq/L. How should the provider interpret this finding?
A. The level is toxic and requires immediate intervention.
B. The level indicates sub-therapeutic dosing.
C. The level is within the therapeutic range.
D. The level is normal for an acute manic episode.
Answer: A
Rationale: The standard therapeutic range for lithium is generally between 0.6 and 1.2
mEq/L. Levels above 1.5 mEq/L are considered toxic and can lead to severe neurological
,and renal complications. Manifestations such as ataxia, coarse tremors, and confusion are
clinical indicators that the dosage needs to be reduced or stopped.
4. Which antidepressant is contraindicated in patients with a history of seizure disorders or
eating disorders?
A. Sertraline
B. Escitalopram
C. Fluoxetine
D. Bupropion
Answer: D
Rationale: Bupropion is known to lower the seizure threshold, making it dangerous for
individuals with pre-existing seizure conditions. Furthermore, it is contraindicated in
patients with anorexia or bulimia due to an increased risk of seizures in those with
electrolyte imbalances. Providers must screen for these conditions before initiating
treatment with this norepinephrine-dopamine reuptake inhibitor.
5. A patient is started on Lamotrigine for mood stabilization. What is the most critical
education the provider must provide regarding adverse effects?
A. The risk of significant weight gain
B. The requirement for weekly blood draws
C. The possibility of developing a life-threatening rash
, D. The high risk of developing diabetes
Answer: C
Rationale: Lamotrigine is associated with Stevens-Johnson Syndrome (SJS), a rare but
potentially fatal dermatological reaction. Patients must be instructed to stop the
medication and seek emergency care at the first sign of a skin rash or mucosal lesion. Slow
titration of the dosage is required to minimize the risk of this severe hypersensitivity
reaction.
6. In the treatment of Alzheimer’s disease, what is the primary mechanism of action of
Donepezil?
A. NMDA receptor antagonism
B. Dopamine reuptake inhibition
C. Serotonin receptor agonism
D. Acetylcholinesterase inhibition
Answer: D
Rationale: Donepezil works by inhibiting the enzyme acetylcholinesterase, which is
responsible for breaking down acetylcholine in the synaptic cleft. By increasing the
availability of acetylcholine, the medication helps to improve cognitive function and
memory in patients with dementia. This pharmacological approach focuses on
compensating for the cholinergic deficit observed in Alzheimer’s pathology.
